Nventa Presents Findings on Proprietary Toll-Like Receptor 3 (TLR3) Agonist, Poly.ICR, at World Vaccine Congress
- Category: Vaccines
- Published on Wednesday, 08 October 2008 02:00
- Hits: 1360
Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant
San Diego, CA, USA | October 08, 2008 | Nventa Biopharmaceuticals Corporation (TSX:NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC–Poly Arginine (Poly-ICR), at the World Vaccine Congress 2008 in Lyon, France. Study results demonstrated Poly-ICR to be a potent vaccine adjuvant targeting the Toll-like Receptor 3 (TLR3) pathway. Data showed that Poly-ICR, in combination with model antigens, elicits strong anti-target antibody and CD8 T-cell immune responses. These findings demonstrate the versatility of Poly-ICR, suggesting that the compound may possess broad potential for use in both therapeutic and prophylactic vaccines.
Additional study findings presented today by Peter Emtage, Ph.D., Nventa’s vice president of research and development, include:
* Poly-ICR is stable and resistant to degradation by RNAses in human serum;
* Poly-ICR induces significant cytokine and chemokine production;
* Poly-ICR matures dendritic cells, known as “the teachers of the immune system”.
In addition to incorporating Poly-ICR into future internal product candidates, Nventa is pursuing the development of Poly-ICR for topical application for the treatment of genital warts (GW) and actinic keratosis, a premalignant condition of the skin.
The company is also currently providing access to Poly-ICR to multiple leading vaccine developers in the U.S. and abroad, who are evaluating Poly-ICR for potential use into a wide range of vaccine products.
“These findings have confirmed the potency of Poly-ICR and highlighted the broad applicability of this compound for potential use in therapeutic and prophylactic vaccines,” said Gregory M. McKee, president and chief executive officer at Nventa. “While we are advancing Poly-ICR for our internal development and use, we’ve been extremely pleased with the interest in Poly-ICR that has been shown by outside parties. We are currently working with vaccine developers worldwide to enable their studies with Poly-ICR and we believe this product will evolve into a revenue generating opportunity for Nventa in the near future.”
Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with a disease-specific antigen can induce both cytotoxic T-cell and antibody (B-cell) immune responses against that antigen. Cytotoxic T-cells, also referred to as CD8 T-cells, are required to target and eliminate pathogen-infected or cancerous cells. Antibodies, or B-cells, are required to protect against an infection caused by a pathogen. Poly-ICR, therefore, has potential utility in both the therapeutic and prophylactic areas of immunotherapy and vaccine development. This novel and potent immunomodulator works with the immune system to induce dendritic cell maturation, along with a broad range of inflammatory cytokines and chemokines, to facilitate the prevention and treatment of infectious diseases or cancer.
Data generated using Poly-ICR, in combination with a tumor-associated antigen, have demonstrated that the addition of the adjuvant potently increases the antigen-specific CD8 T-cell levels, which correlated with regression of tumors and prevention of tumor growth in mouse models. Poly-ICR is differentiated from other Poly IC compositions by its high stability and potency in human sera, as well as its consistency in physical-chemical properties. Nventa has successfully manufactured research and development lots of Poly-ICR and expects that its current manufacturing process can be used to produce future cGMP material.
About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa, please visit www.nventacorp.com.
SOURCE: Nventa Corporation